Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ADXNBullishCorporate Developmentsnews

High materiality8/10

Addex's Neurosterix advances NTX-253 to Phase 2 in schizophrenia

Oct 8, 2026, 1:12 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Phase 1 completion with a clear path to Phase 2 for NTX-253 improves near-term valuation visibility for ADXN via its 20% stake and potential downstream milestones; historically, spin-out progress and multi-part Phase 1/2 transitions in biotech can drive small-cap moves.

AI summary

What happened, with direct paths to the underlying reporting

Addex Therapeutics reports its spin-out Neurosterix has completed Phase 1 testing of NTX-253, a muscarinic M4 positive allosteric modulator for schizophrenia, and will advance to Phase 2. Addex retains a 20% equity stake in Neurosterix, which raised $65 million in a 2024 Series A led by Perceptive Advisors, signaling validation. The Phase 1 design blended healthy volunteers with schizophrenia patients and yielded safety and pharmacokinetic data supportive of upcoming development.

Neurosterix completed Phase 1 for NTX-253; Phase 2 planned in schizophrenia.
NTX-253 is a muscarinic M4 PAM aiming to reduce psychosis with fewer movement issues.
Addex retains 20% equity in Neurosterix; Series A raised $65M in 2024 led by Perceptive Advisors.
Phase 1 combined healthy volunteers and schizophrenia patients; provided safety and PK data.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.